Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Improving adult ALL treatment: pediatric regimens & adding inotuzumab

Richard Stone • 14 Mar 2019
ISAL 2019
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin
CALGB 10403

Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the CALCG 10403 study (NCT00558519), which investigated the use of a pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia (ALL). Doses and schedule in this trial were identical to the Children’s Oncology Group study AALL0232. Prof. Stone then highlights a study going a step further by adding inotuzumab ozogamicin (NCT01363297). This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Richard Stone

2:02
ISAL session highlights: targeting CD123, CD47 & TP53 in AML
Richard Stone • 21 Mar 2023
2:31
Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications
Richard Stone • 21 Mar 2023
1:14
The potential of uproleselan in patients with AML
Richard Stone • 21 Mar 2023
1:57
Insights into the treatment of patients with FLT3-mutated AML & the role of maintenance therapy
Richard Stone • 21 Mar 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals